SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing high volatility as investors weigh contradictory reports and government statements regarding the potential end of the conflict in Iran. While some traders are betting on a sharp reversal based on reports of diplomatic negotiations and ceasefire talk, others remain bullish on the energy sector, citing the continued closure of the Strait of Hormuz and structural supply risks.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is surging as investors react to speculation of a potential de-escalation in the Iran conflict ahead of a high-profile national address. While bulls are driving a broad market rally on hopes for a resolution, the community remains deeply divided and cautious, with many traders questioning the sustainability of the gains given ongoing geopolitical uncertainty and contradictory reports regarding military deployments.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike ($NKE) is facing intense market volatility as shares continue to struggle despite a quarterly earnings beat, with investors weighing the company's long-term turnaround efforts against ongoing concerns over weak sales in China and the impact of tariffs. The community is deeply polarized, with many debating whether the stock is reaching a generational buying opportunity at decade-low levels or if the brand has suffered permanent structural damage due to evolving consumer trends and persistent management challenges.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is rallying sharply as investors react to headlines suggesting potential de-escalation in the Iran conflict, sparking a wave of short-covering and speculative buying. While bullish traders are celebrating the recovery and viewing the volatility as a setup for further upside, market skeptics remain cautious, highlighting that the broader economic impact and ongoing tensions in the Strait of Hormuz could quickly reverse the momentum.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor the upcoming Definitive Feasibility Study and pilot plant milestones while debating the company's management and the accuracy of its project valuations. Community discussion is heavily focused on potential supply chain shifts away from China, speculative catalysts related to geopolitical tensions, and ongoing controversy regarding past technical reporting and share dilution.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors debate the impact of the company's recent earnings report and the strategic implications of its shift away from Chinese markets. While the community is actively discussing the stock's long-term potential as a critical U.S. rare earth supplier and the possibility of a major automaker partnership, price action remains volatile amid broader geopolitical concerns.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently at the center of intense market discourse as investors weigh mixed signals regarding Middle East stability against its potential growth as an EV and AI pioneer. The community remains deeply divided, with many debating the impact of upcoming delivery numbers and executive leadership changes on the stock's long-term momentum.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community speculation as investors weigh upcoming financial disclosures against the companys strategic positioning in the AI and photonics sectors. While some discuss the long-term potential of its optical engine production ramp and ecosystem partnerships, others remain focused on the lack of major revenue catalysts and historical volatility.

Ganymede

Ganymede is capturing attention through steady price action and clean accumulation patterns that have the community feeling confident in the asset's structural integrity. Investors are actively discussing the potential for a breakout, characterized by disciplined buying pressure and a lack of forced volatility.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy (GLND) is drawing intense market attention following its recent SPAC merger and the secured drilling agreement with Stampede Drilling for its massive Jameson Land Basin project. While bulls point to a potential multi-billion barrel oil reserve and strategic geopolitical importance as catalysts for long-term growth, the community remains divided, with active discussions focusing on high-risk exploration, extreme volatility, and polarized debates regarding its status as either a legitimate energy play or a speculative pump-and-dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Healthcare Stocks To Watch Now - March 31st

UnitedHealth Group, Johnson & Johnson, Hims & Hers Health, Intuitive Surgical, McKesson, Medtronic, and Medline are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies involved in delivering medical pro...

Hims & Hers Expands Personalized Digital Healthcare Platform

HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.

<ul class="summary-bullets"><li>In February 2025, Hims &amp; Hers announced the acquisition of a peptide facility in California to meet the growing demand among Americans for personalized healthcare and treatment options.</li><li>An NYT report stated that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official.</li><li>On a recent episode of the Joe Rogan podcast, Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA, said he is a “big fan” of peptides.</li></ul>Hims &amp; Hers Health Inc. (HIMS) shares surged on Tuesday morning amid a report stating that the U.S. Food and Drug Administration is moving to lift restrictions on peptides.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/03/31/health/peptide-ban-fda-rfk-jr.html">report</a> by The New York Times, the FDA is moving to allow compounding pharmacies to manufacture over a dozen injectable peptides&nbsp;that were previously banned due to potential safety risks.This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.<a href="https://stocktwits.com/symbol/HIMS">Shares of Hims &amp; Hers</a>, which provides compounded medications, surged more than 7% in Tuesday morning’s trade.<h2 class="st-heading-2">Top FDA Leaders Have Reservations About Peptides, Says Report</h2>The report added that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official. It noted that if the FDA had flagged peptides as being marketed through unproven claims of disease-fighting and cosmetic benefits.In its 2023 notification, the regulator listed several bulk drug substances, including peptides, noting that it had identified “potential significant safety risks” associated with them.<h2 class="st-heading-2">RFK Jr. Says He Is A ‘Big Fan’ Of Peptides</h2>During an episode of the Joe Rogan podcast earlier this month, Secretary of Health and Human Services Robert F. Kennedy Jr. said that he is a “big fan” of peptides. As the HHS secretary, RFK Jr. oversees the FDA.“I’ve used them myself, and used them with really good effect on a couple of injuries,” he said, while adding that during the Biden administration, 19 peptides were “illegally” moved to Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.This category prohibits compounding pharmacies from formulating compounds comprising peptides, RFK Jr. added.“There was huge demand for peptides and a black market came up, and the black market is run by companies that say the peptides are for animal use or research purposes. And that peptide now basically completely replaced the legal market,” he said.<h2 class="st-heading-2">Where Does Hims &amp; Hers Fit In This Case?</h2>Hims &amp; Hers had come&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">under fire</a> from regulators and Novo Nordisk AS (NVO) for offering a compounded version of the company’s best-selling weight-loss pill, Wegovy.Novo Nordisk subsequently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> its lawsuit against Hims &amp; Hers and announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Earlier in February 2025, Hims &amp; Hers announced the acquisition of a peptide facility based in California to address the growing demand from Americans for personalized healthcare and treatment options.“The peptide capabilities made possible through this acquisition position the company in the coming years to explore exciting advances in peptide innovation, including across areas of consumer need such as preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistance,” the company said.<h2 class="st-heading-2">What Are Peptides?</h2>Peptides are short chains of amino acids, the same building blocks that make up proteins, linked together by peptide bonds.Blockbuster weight-loss drugs Ozempic and Wegovy are also peptide medications that use glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity by&nbsp;stimulating insulin secretion.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 39% year-to-date and 33% over the past 12 months. The iShares Core S&amp;P Mid-Cap ETF (IJH) is up 14% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides

This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.

Equity

Hims & Hers Health, Inc. (HIMS) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.78, denoting a -3.1% move from the preceding trading day.

SG Americas Securities LLC Boosts Stock Position in Hims & Hers Health, Inc. $HIMS

SG Americas Securities LLC raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 25.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 371,553 shares of the company's stock after purchasing an ad...

TD Cowen Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

TD Cowen lowered their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating for the company in a report on Friday...

Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill

(RTTNews) - Hims & Hers Health Inc. (HIMS) announced that a wide range of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers. This includes the Wegovy pill, the...

Healthcare Stocks To Consider - March 26th

UnitedHealth Group, Johnson & Johnson, Cencora, Medtronic, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in delivering medical goods and servicessuch as pharmaceutical and biot...

What's Happening With Novo Nordisk Stock Today?

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA approved GLP 1 medications, including...

<ul class="summary-bullets"><li>Wegovy will be initially available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, with a higher 7.2 mg dose to be available later, HIMS said.</li><li>Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses.</li><li>HIMS will also introduce a weight-loss membership starting at $39 for the first month, then $149 per month thereafter.</li></ul>Hims &amp; Hers Health Inc (HIMS) grabbed retail attention on Thursday after launching a broad lineup of Novo Nordisk GLP-1 medications on its platform, including the FDA-approved Wegovy pill. The rollout comes just weeks after Novo dropped its patent infringement lawsuit against Hims related to its blockbuster weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> was down more than 3%, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed nearly 2% higher at the time of writing.<h2 class="st-heading-2">Wegovy To Be Available In Several Doses</h2>HIMS said that eligible patients will have access to multiple treatment options, including Wegovy in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, and 1.5 mg, 4 mg, 9 mg, and 25 mg pill forms. A 7.2 mg injection will be available later, the company said.Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses for the management of Type 2 diabetes. It has not been approved by the FDA for weight loss.HIMS is introducing a new&nbsp;weight-loss&nbsp;membership that provides comprehensive support, including 24/7 access to healthcare providers, personalized nutrition guidance, regular check-ins, and a peer support community. Membership will start at $39 for the first month, followed by $149 per month thereafter.<h2 class="st-heading-2">Legal Battle Over Compounded Drugs</h2>Last month, Novo Nordisk filed a patent infringement lawsuit against Hims &amp; Hers after the telehealth company introduced a low-cost, compounded version of the Wegovy pill for $49 per month, claiming it contained the same active ingredient as the branded drug. Novo argued that the products violated its patents and misled consumers about safety and effectiveness, prompting the FDA to warn about the use of GLP-1 ingredients in unapproved compounded drugs.However, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> the lawsuit earlier this month and instead formed a partnership with Hims &amp; Hers, allowing the company to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices. Hims &amp; Hers also announced it would stop marketing compounded GLP-1 drugs and transition existing patients to FDA-approved treatments.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for both HIMS and NVO remained in the ‘bearish’ territory over the past 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/HIMS_jpg_50a2aae200.webp" alt="HIMS.jpg" width="855" height="94"><figcaption>HIMS' Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_c11986072f.webp" alt="NVO.jpg" width="862" height="102"><figcaption>NVO's Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure>One user said they were going long after the news came out.<stembedurl>https://stocktwits.com/turnaroundtuesdays01/message/648651986</stembedurl>Year-to-date, HIMS stock has declined by about 37%, while NVO stock has fallen by about 29%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-anktiva-trial-update-bladder-cancer-phase-2-idmc/cZ3rwRfRIjw">ImmunityBio Says Phase 2 Bladder Cancer Trial Has ‘Statistical Power’ – Anktiva-BCG Advances Toward Filing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform

Eligible patients will be able to access multiple treatment options, including Wegovy in several injection doses and pill forms, as well as Ozempic injection pens.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Investors are closely watching potential FDA moves to lift restrictions on compounding popular injectable peptides, viewing it as a massive growth engine.

Long-term bulls are aggressively betting on a violent squeeze, arguing that high short interest will backfire when institutional sentiment shifts.

Debate persists over the company's ability to defend profit margins against Big Pharma competition and rising operational expenses.

Traders are struggling with recent erratic price swings and a lack of correlation to broader market performance during the ongoing war.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.01	--	--	N/A
Q4 '25	$0.04	$0.08	100.62%	BEAT
Q3 '25	$0.09	$0.06	-36.40%	MISSED
Q2 '25	$0.15	$0.17	12.73%	BEAT
Q1 '25	$0.12	$0.20	65.41%	BEAT

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest HIMS News

HIMSHims & Hers Health Inc